CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy
Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL) with KMT2A rearrangements following chemotherap...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/10/e009499.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849324005508513792 |
|---|---|
| author | Nisha Patel Adam Lamble Ilan Kirsch Haneen Shalabi Hao-Wei Wang Sara K. Silbert Samantha Scanlon Constance M Yuan Alyssa Doverte Jake Wellek Raul Braylan Mark Ahlman Evrim B Turkbey Sandra D Bohling Karen M Chisholm Murat Alp Oztek Mike LaLoggia Anupam Verma Alexandra E Kovach Brent L Wood Kasey Leger Nirali N. Shah |
| author_facet | Nisha Patel Adam Lamble Ilan Kirsch Haneen Shalabi Hao-Wei Wang Sara K. Silbert Samantha Scanlon Constance M Yuan Alyssa Doverte Jake Wellek Raul Braylan Mark Ahlman Evrim B Turkbey Sandra D Bohling Karen M Chisholm Murat Alp Oztek Mike LaLoggia Anupam Verma Alexandra E Kovach Brent L Wood Kasey Leger Nirali N. Shah |
| author_sort | Nisha Patel |
| collection | DOAJ |
| description | Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL) with KMT2A rearrangements following chemotherapy, but is now increasingly being observed as a form of immune escape following targeted therapies among children and adults with B-ALL with and without KMT2A rearrangements. In this report, we present two cases of adolescents with B-ALL harboring CRLF2 rearrangements (Philadelphia-like phenotype) who developed LS to acute myeloid leukemia following CD19 targeted therapy. To our knowledge, these are the first cases of LS to be reported in patients with CRLF2 rearranged acute lymphoblastic leukemia. In addition to raising awareness that this genetic mutation may associate with lineage plasticity, our cases illustrate the importance of multi-modal disease surveillance in the diagnosis of LS. |
| format | Article |
| id | doaj-art-c7eef0e46fe34bf3a2c08de396cd97b7 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-c7eef0e46fe34bf3a2c08de396cd97b72025-08-20T03:48:51ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-10-01121010.1136/jitc-2024-009499CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapyNisha Patel0Adam Lamble1Ilan Kirsch2Haneen Shalabi3Hao-Wei Wang4Sara K. Silbert5Samantha Scanlon6Constance M Yuan7Alyssa Doverte8Jake Wellek9Raul Braylan10Mark Ahlman11Evrim B Turkbey12Sandra D Bohling13Karen M Chisholm14Murat Alp Oztek15Mike LaLoggia16Anupam Verma17Alexandra E Kovach18Brent L Wood19Kasey Leger20Nirali N. Shah21Hematology Section, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USADepartment of Pediatric Hematology & Oncology, University of Washington, Seattle, Washington, USAAdaptive Biotechnologies, Seattle, Washington, USANational Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USALaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USANational Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USADepartment of Pediatric Hematology & Oncology, University of Washington, Seattle, Washington, USALaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USALaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USALaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USAHematology Section, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USADepartment of Radiology and Imaging, Medical College of Georgia, Augusta, Georgia, USARadiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland, USADepartment of Laboratories, Seattle Children’s Hospital, Seattle, Washington, USADepartment of Laboratories, Seattle Children’s Hospital, Seattle, Washington, USADepartment of Radiology, University of Washington, Seattle, Washington, USALake Erie College of Osteopathic Medicine, Rochester, New York, USANational Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USAHematopathology, Department of Pathology and Laboratory Medicine, Children`s Hospital Los Angeles, Los Angeles, California, USAHematopathology, Department of Pathology and Laboratory Medicine, Children`s Hospital Los Angeles, Los Angeles, California, USADepartment of Pediatric Hematology & Oncology, University of Washington, Seattle, Washington, USANational Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USALineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL) with KMT2A rearrangements following chemotherapy, but is now increasingly being observed as a form of immune escape following targeted therapies among children and adults with B-ALL with and without KMT2A rearrangements. In this report, we present two cases of adolescents with B-ALL harboring CRLF2 rearrangements (Philadelphia-like phenotype) who developed LS to acute myeloid leukemia following CD19 targeted therapy. To our knowledge, these are the first cases of LS to be reported in patients with CRLF2 rearranged acute lymphoblastic leukemia. In addition to raising awareness that this genetic mutation may associate with lineage plasticity, our cases illustrate the importance of multi-modal disease surveillance in the diagnosis of LS.https://jitc.bmj.com/content/12/10/e009499.full |
| spellingShingle | Nisha Patel Adam Lamble Ilan Kirsch Haneen Shalabi Hao-Wei Wang Sara K. Silbert Samantha Scanlon Constance M Yuan Alyssa Doverte Jake Wellek Raul Braylan Mark Ahlman Evrim B Turkbey Sandra D Bohling Karen M Chisholm Murat Alp Oztek Mike LaLoggia Anupam Verma Alexandra E Kovach Brent L Wood Kasey Leger Nirali N. Shah CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy Journal for ImmunoTherapy of Cancer |
| title | CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy |
| title_full | CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy |
| title_fullStr | CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy |
| title_full_unstemmed | CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy |
| title_short | CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy |
| title_sort | crlf2 rearranged b cell all with extramedullary lineage switch to aml following cd19 targeted therapy |
| url | https://jitc.bmj.com/content/12/10/e009499.full |
| work_keys_str_mv | AT nishapatel crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT adamlamble crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT ilankirsch crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT haneenshalabi crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT haoweiwang crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT saraksilbert crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT samanthascanlon crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT constancemyuan crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT alyssadoverte crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT jakewellek crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT raulbraylan crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT markahlman crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT evrimbturkbey crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT sandradbohling crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT karenmchisholm crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT muratalpoztek crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT mikelaloggia crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT anupamverma crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT alexandraekovach crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT brentlwood crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT kaseyleger crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy AT niralinshah crlf2rearrangedbcellallwithextramedullarylineageswitchtoamlfollowingcd19targetedtherapy |